SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Elon Musks warning that neocloud providers face failures and consolidation has intensified selling in CoreWeave and renewed concern about its debt-heavy, capital-intensive AI infrastructure model and access to financing. Traders debate whether Musk is criticizing a competitor for self-interest, while bulls point to AI demand and Nvidias backing and bears focus on borrowing costs, dilution, and execution risks.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is under pressure alongside AI data-center and neocloud stocks as traders debate financing risks and Elon Musks warning that tighter credit could trigger failures among smaller operators. Bears fear debt, dilution and execution challenges, while bulls argue IRENs contracts, power access and AI partnerships distinguish it and point to continued compute demand.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is drawing attention amid a sharp neocloud selloff tied to Elon Musks warning of tighter financing and consolidation among AI infrastructure providers, intensifying concerns about debt-funded expansion and data-center returns. Traders disagree on whether Nebius is vulnerable to sector-wide risks or better positioned because of its financing access and demand for AI compute.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Modernas Phase 3 melanoma-vaccine results with Merck are driving discussion: traders broadly view the data as clinically promising, but the shares sold off as investors judged them against high expectations after a sharp rally. Bulls see validation for a broader cancer-vaccine platform, while bears question its commercial potential, costs and valuation.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on SELLASs REGAL Phase 3 trial of GPS for AML, with traders watching for the 80th survival event that would trigger final analysis and eventual topline results. The prolonged wait and company silence fuel debate: bulls speculate that slower event accrual reflects longer survival and possible ASH-related disclosure, while skeptics warn that the delay is uncertain and could signal problems; SLS009 data is a secondary focus.

iShares Inc. - iShares MSCI Brazil ETF

iShares MSCI Brazil ETF

Brazilian equities sold off sharply after Lulas election victory, as traders voiced concerns about policy and economic uncertainty; some alleged election irregularities without evidence. Others called the move an overreaction and viewed the drop as a buying opportunity.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digitals steep selloff is dominating discussion, with traders citing the recent convertible offering and dilution concerns, possible hedging-related selling, and broader weakness in AI data-center stocks. Some see its contracted data-center business and expansion pipeline as long-term support, while others worry about financing, execution, and the upcoming earnings report.

Lufax Holding Ltd. operates a technology-empowered personal financial services platform. It offers personal lending and wealth management solutions. The company was founded in August 2005 and is headquartered in Shanghai, China.

Lufax Holding Ltd - ADR

Lufaxs preliminary Q3 loss warning and planned reverse split are driving debate ahead of the full results: bearish traders see more evidence of business and shareholder risk, while some holders argue tax charges and credit provisions may distort the headline loss and are watching loan quality and originations for signs of improvement. Discussion also reflects broader weakness across Chinese fintech lenders and mistrust of management.

MARA Holdings, Inc. is a digital asset technology company, which engages in mining cryptocurrencies with a focus on the Bitcoin ecosystem. It also deals with owning and operating bitcoin mining facilities or data centers, selling proprietary software or technology to third parties operating in the Bitcoin ecosystem, offering advisory and consulting services to support Bitcoin mining ventures in domestic and international jurisdictions, and generating electricity from renewable energy resources or methane gas capture to power Bitcoin mining projects. The company was founded on February 23, 2010 and is headquartered in Hallandale Beach, FL.

MARA Holdings Inc.

Marathon Digital Holdings Inc

MARAs prolonged selloff and steep underperformance versus Bitcoin dominate discussion, with traders focused on the lack of signed AI/data-center tenants and uncertainty around the Long Ridge deal and financing. Bears cite debt, dilution and management concerns, while bulls see an oversold setup and argue Bitcoin strength or a lease announcement could support a rebound.

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

Agenus Inc

Agenuss BOT+BAL neoadjuvant colon-cancer data, including a reported 72% pathologic complete response rate in a small Phase 2 dMMR cohort, are driving attention; traders highlight the possibility of organ preservation. Optimists see promising efficacy, while skeptics question the early, limited dataset and stress the need for durable results and confirmatory Phase 3 progress.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?

Xenon pauses enrollment in late-stage depression trials after unexpected side effects, while its epilepsy pipeline offers growth potential.

Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month

Equity

CEO Ian Mortimer and CFO Thomas Kelly purchased 45,000 shares of XENE in the open market.


XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Xenon Pharmaceuticals Inc. (Xenon or the Company) (NASDAQ: XENE) for violations of the securities laws. INVESTIGATION DETAILS: The investigation...

Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)

Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE) Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)PR NewswireNEW YORK, Sept. 22, 2026...

Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment

Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment...

Stocks making the biggest moves midday: Netflix, Xenon Pharmaceuticals, Coinbase, Sandisk, SpaceX & more

Here are some of the companies making headlines in midday trading...

Xenon Stock Reaction Is Overblown: Analyst

Xenon Pharmaceuticals submits an FDA application for azetukalner for seizures while voluntarily pausing enrollment in depression trials.read more...

XENE Files NDA for Epilepsy Drug, Falls on Depression Studies' Setback

Xenon files an FDA application for azetukalner in epilepsy as its depression studies face a temporary enrollment pause.

Xenon Pharmaceuticals (XENE) Shares Fall 25% After Hours: Here's Why

Xenon Pharmaceuticals shares fell 25% after hours after pausing new patient enrollment in ongoing psychiatry clinical studies.read more...

Aethlon Medical, Oklo, CID HoldCo, Xenon Pharmaceuticals and Moderna: Why These 5 Stocks Are on Investors' Radars Today

Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to 51,778.04read more...

Xenon Pharmaceuticals, Inc. is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Xenon Pharmaceuticals Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Last month, Xenon submitted Azetukalner to the FDA for focal onset seizures.</li><li>Xenon ended Q2 with about $1.25 billion in cash and investments, which management expects to fund operations into 2029.</li><li>The company’s pipeline also includes pain treatments, including XEN1701, XEN1120 and XEN1720.</li></ul>Xenon Pharmaceuticals (<a class="mention" data-mention="$XENE" data-symbol-id="XENE" href="https://stocktwits.com/symbol/XENE" target="_blank">XENE</a>) was on investors’ radar on Thursday after the biotech company’s top executives bought a combined $1.68 million in shares, as the company advances its lead epilepsy drug, Azetukalner.On Thursday, CEO Ian Mortimer bought 30,000 shares at $37.38 apiece, worth about $1.12 million, while CFO Thomas Kelly purchased 15,000 shares at $37.316, worth nearly $560,000, according to regulatory filings. Earlier in the year, Mortimer sold 40,000 shares for roughly $1.78 million.At the time of writing, <a href="https://stocktwits.com/symbol/XENE">XENE shares</a> were up 5%, clocking their biggest single-day gains in more than a month.<h2 class="st-heading-2">Azetukalner Is Xenon’s Biggest Catalyst</h2>Xenon is a clinical-stage biotech company with no approved commercial product. Its lead drug is Azetukalner, which is being developed for epilepsy, major depressive disorder, and bipolar depression.Last month, Xenon <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.xenon-pharma.com/news-releases/news-release-details/xenon-announces-azetukalner-nda-submission-fda-focal-seizures">submitted</a> Azetukalner to the FDA for the treatment of focal onset seizures, following positive Phase 2b and Phase 3 trial results. The FDA has not yet announced whether it has accepted the application for review. If it accepts the application, the agency would set a target date (PDUFA) for its decision on whether to approve the drug.Separately, Xenon is also testing Azetukalner for depression. The company temporarily paused enrollment of new patients in its psychiatry studies after observing neuropsychiatric side effects, but said the pause does not affect its epilepsy program. Results are expected in the first quarter of 2027.The company is also building a pipeline of experimental pain treatments, including XEN1701, XEN1120 and XEN1720. All three are in early-stage clinical development.<h2 class="st-heading-2">Cash Position Remains Strong</h2>Xenon generated no revenue in the second quarter (Q2) and posted a net loss of $110.7 million, or $1.11 per share, as it continued spending heavily on clinical development.However, Xenon ended the June quarter with about $1.25 billion in cash, cash equivalents and marketable securities. Management expects that balance to fund operations into 2029.<h2 class="st-heading-2">Retail’s Take On <a class="mention" data-mention="$XENE" data-symbol-id="XENE" href="https://stocktwits.com/symbol/XENE" target="_blank">XENE</a></h2>Retail sentiment for <a class="mention" data-mention="$XENE" data-symbol-id="XENE" href="https://stocktwits.com/symbol/XENE" target="_blank">XENE</a> on Stocktwits turned ‘neutral’ from ‘bearish’ over the past 24 hours.<a class="mention" data-mention="$XENE" data-symbol-id="XENE" href="https://stocktwits.com/symbol/XENE" target="_blank">XENE</a> shares have fallen 12% so far this year, underperforming the broader State Street SPDR S&amp;P Biotech (XBI) ETF’s 29% gains.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/fhtx-stock-on-track-for-record-low-why-did-foghorn-and-lilly-pull-the-plug-on-cancer-drug/cZD030MRBis">&nbsp;FHTX Stock On Track For Record Low — Why Did Foghorn And Lilly Pull The Plug On Cancer Drug?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Xenon Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

CEO Ian Mortimer and CFO Thomas Kelly purchased 45,000 shares of XENE in the open market.

SPDR S&P Biotech ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$35.34
Prev Close	$36.50
Open	$36.62
Dividend Yield	0.00%
50-Day Moving Average	$47.88
Beta	0.86
Avg. Volume	2.32M
PE Ratio	-7.45

52-Week High	$72.66
52-Week Low	$33.38
Market Capitalization	$3.42B
EPS (Annual)	-$4.36
Price to Book	2.75
Revenue Per Employee	$20,270.27

Feed

News

Sentiment

Earnings

Fundamentals

Info

XENE Fundamentals